1054 citations
,
February 1998 in “The New England Journal of Medicine” In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.
29 citations
,
April 1995 in “Endocrinology” In this study, finasteride treatment did not negatively impact bone development or density in male rats, suggesting that DHT deficiency is not harmful to the male rat skeleton.
48 citations
,
November 1992 in “Clinical Endocrinology” Long-term finasteride use doesn't change bone density or metabolism.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.